TKD peptide as a ligand targeting drug delivery systems to memHsp70-positive breast cancer
Breast cancer has been considered as a serious threat to females' life. Active targeting drug delivery is a potential strategy in cancer therapy, which however is hindered by the targeting efficiency. Herein, a 14-mer peptide (TKD) derived from the oligomerization domain of membrane heat-shock protein 70 (memHsp70), for the first time, was exploited as a tumor-targeting ligand to modify polymeric micelles. NMR results demonstrated the successful synthesis of TKD-PEG-PLGA polymer. No difference was observed in the drug release between TKD-modified doxorubicin (DOX)-loaded micelles (TKD-D-M) and unmodified counterparts. The modification of TKD mediated apparently higher cellular uptake within memHsp70-positive MCF-7 cells, compared to normal MCF-10A cells. Excessive TKD pretreatment significantly inhibited the cellular uptake of TKD-D-M, indicating the receptor-mediated mechanism. Enhanced accumulation of TKD-D-M within the tumor of MCF-7 bearing mice further demonstrated the targeting ability of TKD in vivo. CCK-8 assay showed that the modification of TKD significantly increase the anti-proliferation effect against MCF-7 cells. The findings demonstrated that TKD peptide is a potential ligand which can target drug delivery systems to memHsp70-positive breast cancer..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:498 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 498(2016), 1-2, Seite 40-48 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meng, Ying [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1016/j.ijpharm.2015.12.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1971814687 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1971814687 | ||
| 003 | DE-627 | ||
| 005 | 20230516215806.0 | ||
| 007 | tu | ||
| 008 | 160308s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2015.12.013 |2 doi | |
| 028 | 5 | 2 | |a PQ20160430 |
| 035 | |a (DE-627)OLC1971814687 | ||
| 035 | |a (DE-599)GBVOLC1971814687 | ||
| 035 | |a (PRQ)c1295-19862d5eb1133cff4e1c65fbf4ddf8b434c7499a8cea7b653806a24d4bb14d420 | ||
| 035 | |a (KEY)0052117520160000498000100040tkdpeptideasaligandtargetingdrugdeliverysystemstom | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Meng, Ying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TKD peptide as a ligand targeting drug delivery systems to memHsp70-positive breast cancer |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Breast cancer has been considered as a serious threat to females' life. Active targeting drug delivery is a potential strategy in cancer therapy, which however is hindered by the targeting efficiency. Herein, a 14-mer peptide (TKD) derived from the oligomerization domain of membrane heat-shock protein 70 (memHsp70), for the first time, was exploited as a tumor-targeting ligand to modify polymeric micelles. NMR results demonstrated the successful synthesis of TKD-PEG-PLGA polymer. No difference was observed in the drug release between TKD-modified doxorubicin (DOX)-loaded micelles (TKD-D-M) and unmodified counterparts. The modification of TKD mediated apparently higher cellular uptake within memHsp70-positive MCF-7 cells, compared to normal MCF-10A cells. Excessive TKD pretreatment significantly inhibited the cellular uptake of TKD-D-M, indicating the receptor-mediated mechanism. Enhanced accumulation of TKD-D-M within the tumor of MCF-7 bearing mice further demonstrated the targeting ability of TKD in vivo. CCK-8 assay showed that the modification of TKD significantly increase the anti-proliferation effect against MCF-7 cells. The findings demonstrated that TKD peptide is a potential ligand which can target drug delivery systems to memHsp70-positive breast cancer. | ||
| 540 | |a Nutzungsrecht: Copyright © 2015 Elsevier B.V. All rights reserved. | ||
| 700 | 1 | |a Wang, Shanshan |4 oth | |
| 700 | 1 | |a Li, Chengyi |4 oth | |
| 700 | 1 | |a Qian, Min |4 oth | |
| 700 | 1 | |a Zheng, Yufan |4 oth | |
| 700 | 1 | |a Yan, Xueying |4 oth | |
| 700 | 1 | |a Huang, Rongqin |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d Amsterdam : Elsevier [u.a.], 1978 |g 498(2016), 1-2, Seite 40-48 |w (DE-627)130037605 |w (DE-600)428962-6 |w (DE-576)015579328 |x 0378-5173 |7 nnns |
| 773 | 1 | 8 | |g volume:498 |g year:2016 |g number:1-2 |g pages:40-48 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.ijpharm.2015.12.013 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26680317 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 498 |j 2016 |e 1-2 |h 40-48 | ||